Join Vivian A. Fonesca, MD, FRCP, as he shares his thoughts on the results of the phase III LEADER trial, which demonstrated a cardiovascular benefit for liraglutide in patients with type 2 diabetes who have cardiovascular disease.
Vivian A. Fonseca, MD, FRCP, discusses best practices for the management of type 2 diabetes based on the latest guidelines and emerging treatment approaches.
In this downloadable slideset, Vivan A. Fonseca, MD, FRCP, reviews best practices and recent treatment advances in the management of patients with type 2 diabetes.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.